Creabilis
Creabilis is a European specialty pharmaceutical company focused on developing and commercializing innovative treatments for dermatological and inflammatory diseases. The company has a strong emphasis on addressing significant unmet medical needs in skin disorders, which presents high commercial potential. Its most advanced product is CT327, a topical treatment aimed at chronic pruritus, which is set to enter Phase II clinical trials. Creabilis also aims to establish a pruritus franchise around CT327 and another candidate, CT340, both developed using its proprietary Low Systemic Exposure platform technology. Additionally, Creabilis has a robust pipeline of clinical and pre-clinical drug candidates generated from its extensive research in dermatology.
Nautilus Biotech
Venture Round in 2007
Nautilus Biotech is a biotechnology company. The company has a pipeline of therapeutic proteins with improved profiles. The company's products include Belerofon, an injectable and orally available interferon alpha for use in the treatment of chronic Hepatitis C infection; and Vitatropin, an injectable and orally available human growth hormone (hGH) for use in the treatment of growth deficiencies. Nautilus Biotech S.A. sells therapeutic proteins, including interferons, hormones, growth factors, and enzymes in France and internationally. The company's protein engineering technology improves the pharmacology profile and administration route of blockbuster protein drugs. Nautilus Biotech S.A. was founded in 1999 and is based in Evry, France.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.